已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

医学 德诺苏马布 唑来膦酸 前列腺癌 临床终点 内科学 肿瘤科 安慰剂 泌尿科 癌症 随机对照试验 骨质疏松症 病理 替代医学
作者
Karim Fizazi,Michael A. Carducci,Matthew R. Smith,Ronaldo Damiâo,Janet E. Brown,Lawrence I. Karsh,Piotr Milecki,Neal D. Shore,Michael Rader,Huei Wang,Qi Jiang,Sylvia Tadros,Roger Dansey,Carsten Goessl
出处
期刊:The Lancet [Elsevier BV]
卷期号:377 (9768): 813-822 被引量:1916
标识
DOI:10.1016/s0140-6736(10)62344-6
摘要

Bone metastases are a major burden in men with advanced prostate cancer. We compared denosumab, a human monoclonal antibody against RANKL, with zoledronic acid for prevention of skeletal-related events in men with bone metastases from castration-resistant prostate cancer.In this phase 3 study, men with castration-resistant prostate cancer and no previous exposure to intravenous bisphosphonate were enrolled from 342 centres in 39 countries. An interactive voice response system was used to assign patients (1:1 ratio), according to a computer-generated randomisation sequence, to receive 120 mg subcutaneous denosumab plus intravenous placebo, or 4 mg intravenous zoledronic acid plus subcutaneous placebo, every 4 weeks until the primary analysis cutoff date. Randomisation was stratified by previous skeletal-related event, prostate-specific antigen concentration, and chemotherapy for prostate cancer within 6 weeks before randomisation. Supplemental calcium and vitamin D were strongly recommended. Patients, study staff, and investigators were masked to treatment assignment. The primary endpoint was time to first on-study skeletal-related event (pathological fracture, radiation therapy, surgery to bone, or spinal cord compression), and was assessed for non-inferiority. The same outcome was further assessed for superiority as a secondary endpoint. Efficacy analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00321620, and has been completed.1904 patients were randomised, of whom 950 assigned to denosumab and 951 assigned to receive zoledronic acid were eligible for the efficacy analysis. Median duration on study at primary analysis cutoff date was 12·2 months (IQR 5·9-18·5) for patients on denosumab and 11·2 months (IQR 5·6-17·4) for those on zoledronic acid. Median time to first on-study skeletal-related event was 20·7 months (95% CI 18·8-24·9) with denosumab compared with 17·1 months (15·0-19·4) with zoledronic acid (hazard ratio 0·82, 95% CI 0·71-0·95; p = 0·0002 for non-inferiority; p = 0·008 for superiority). Adverse events were recorded in 916 patients (97%) on denosumab and 918 patients (97%) on zoledronic acid, and serious adverse events were recorded in 594 patients (63%) on denosumab and 568 patients (60%) on zoledronic acid. More events of hypocalcaemia occurred in the denosumab group (121 [13%]) than in the zoledronic acid group (55 [6%]; p<0·0001). Osteonecrosis of the jaw occurred infrequently (22 [2%] vs 12 [1%]; p = 0·09).Denosumab was better than zoledronic acid for prevention of skeletal-related events, and potentially represents a novel treatment option in men with bone metastases from castration-resistant prostate cancer.Amgen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Maestro_S的应助被渡增越采纳,获得10
1秒前
2秒前
2秒前
xuzixi完成签到,获得积分20
3秒前
路易斯完成签到 ,获得积分10
3秒前
超帅慕晴完成签到,获得积分10
3秒前
何ql完成签到,获得积分10
4秒前
6wdhw完成签到 ,获得积分10
6秒前
季风气候完成签到 ,获得积分10
6秒前
7秒前
李健的小迷弟的应助被李jy采纳,获得30
7秒前
weihuh完成签到,获得积分10
7秒前
9W完成签到,获得积分10
8秒前
zhai完成签到 ,获得积分10
8秒前
zyd完成签到,获得积分10
8秒前
蚊籽完成签到 ,获得积分10
10秒前
10秒前
呼啦啦完成签到 ,获得积分10
11秒前
mps完成签到 ,获得积分10
11秒前
keep完成签到,获得积分10
11秒前
xuzixi关注了科研通微信公众号
12秒前
Jun完成签到,获得积分10
12秒前
xurilaixi完成签到,获得积分10
12秒前
12秒前
曹定完成签到 ,获得积分10
13秒前
KeldonHuang完成签到,获得积分10
14秒前
Jun发布了新的文献求助10
14秒前
daidaie发布了新的文献求助30
14秒前
sleepydoudou完成签到,获得积分10
15秒前
飘落的樱花完成签到,获得积分10
15秒前
zzzxxxxxyyyyy完成签到 ,获得积分10
16秒前
Amor完成签到,获得积分10
16秒前
科研小天才完成签到 ,获得积分10
16秒前
16秒前
16秒前
Rain完成签到 ,获得积分10
17秒前
腼腆的妖妖完成签到 ,获得积分10
17秒前
孤独的鹰完成签到,获得积分10
17秒前
YHF2完成签到,获得积分10
19秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158391
求助须知:如何正确求助?哪些是违规求助? 9554206
关于积分的说明 21718287
捐赠科研通 7747762
什么是DOI,文献DOI怎么找? 3426964
关于科研通互助平台的介绍 2551704
邀请新用户注册赠送积分活动 2471132